Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800
Debt
Debt-to-Equity Ratio0.04
Current Ratio10.22
Quick Ratio10.22
Price-To-Earnings
Trailing P/E Ratio-12.14
Forward P/E Ratio-10.79
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.64 per share
Price / Book6.99
Profitability
EPS (Most Recent Fiscal Year)($1.52)
Net Income$-35,430,000.00
Net MarginsN/A
Return on Equity-48.67%
Return on Assets-42.06%
Miscellaneous
Employees32
Outstanding Shares37,970,000
Market Cap$725.33 million
Kura Oncology (NASDAQ:KURA) Frequently Asked Questions
What is Kura Oncology's stock symbol?
Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
How were Kura Oncology's earnings last quarter?
Kura Oncology Inc (NASDAQ:KURA) released its quarterly earnings data on Thursday, August, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.45). View Kura Oncology's Earnings History.
When is Kura Oncology's next earnings date?
What price target have analysts set for KURA?
6 brokerages have issued 1-year price targets for Kura Oncology's shares. Their predictions range from $19.00 to $35.00. On average, they anticipate Kura Oncology's share price to reach $28.00 in the next year. This suggests a possible upside of 51.8% from the stock's current price. View Analyst Price Targets for Kura Oncology.
What is the consensus analysts' recommendation for Kura Oncology?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.
What are Wall Street analysts saying about Kura Oncology stock?
Here are some recent quotes from research analysts about Kura Oncology stock:
- 1. Cann analysts commented, "The KO-947 phase I program is on track for an on-time enrollment, with data expected in the second half of this year from the phase I study. Findings presented at AACR today could inform future clinical studies for KO-947, by targeting a subset of head and neck, and esophageal patients, based on a precision medicine model. We conclude that KO-947 continues to be a promising asset, based on preclinical data, but is not anticipated to have revenue impact to Kura Oncology by 2022; therefore, we are not making any adjustments to our estimates or outlook." (4/17/2018)
- 2. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (3/22/2018)
Who are some of Kura Oncology's key competitors?
Some companies that are related to Kura Oncology include Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT), Myokardia (MYOK), Akorn (AKRX), Spectrum Pharmaceuticals (SPPI), Xencor (XNCR), Cambrex (CBM), PTC Therapeutics (PTCT), AnaptysBio (ANAB) and Phibro Animal Health (PAHC).
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the folowing people:
- Dr. Troy Edward Wilson, Chairman, CEO, Pres, CFO & Principal Accounting Officer (Age 49)
- Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 53)
- Ms. Heidi Henson, Consultant (Age 52)
- Mr. John Farnam, Chief Operating Officer
- Dr. Yi Liu Ph.D., Chief Scientific Officer (Age 50)
Has Kura Oncology been receiving favorable news coverage?
Media stories about KURA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kura Oncology earned a news and rumor sentiment score of 0.12 on Accern's scale. They also assigned news stories about the company an impact score of 47.63 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Kura Oncology.
Who are Kura Oncology's major shareholders?
Kura Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (8.87%), BlackRock Inc. (5.27%), Victory Capital Management Inc. (4.53%), Eagle Asset Management Inc. (4.16%), Partner Fund Management L.P. (2.86%) and Carillon Tower Advisers Inc. (2.82%).
Which major investors are selling Kura Oncology stock?
KURA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Partner Fund Management L.P., Spark Investment Management LLC, Assenagon Asset Management S.A., Tiverton Asset Management LLC, California Public Employees Retirement System, Alps Advisors Inc. and Alps Advisors Inc..
Which major investors are buying Kura Oncology stock?
KURA stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Eagle Asset Management Inc., Carillon Tower Advisers Inc., BlackRock Inc., Prosight Management LP, Sio Capital Management LLC, Point72 Asset Management L.P. and DAFNA Capital Management LLC.
How do I buy shares of Kura Oncology?
Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kura Oncology's stock price today?
One share of KURA stock can currently be purchased for approximately $18.45.
How big of a company is Kura Oncology?
Kura Oncology has a market capitalization of $725.33 million. The company earns $-35,430,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Kura Oncology employs 32 workers across the globe.
How can I contact Kura Oncology?
Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]
MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
